NASDAQ : KRRO
Korro Bio, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 14.315 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 210.80M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 210.80M |
| Enterprise Value | 115.09M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 14.73M |
| Shares Outstanding | 14.73M |
| Shares Change (YoY) | +28.33% |
| Shares Change (QoQ) | +51.90% |
| Owned by Insiders (%) | 0.80% |
| Owned by Institutions (%) | 69.60% |
| Float | 10.58M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 88.50 |
| Forward PS | 240.91 |
| PB Ratio | 2.04 |
| P/TBV Ratio | 2.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 48.32 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 9.55 |
| Quick Ratio | 9.11 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -89.63 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -97.69% |
| Return on Assets (ROA) | -27.95% |
| Return on Invested Capital (ROIC) | -31.50% |
| Return on Capital Employed (ROCE) | -50.99% |
| Weighted Average Cost of Capital (WACC) | 14.62% |
| Revenue Per Employee | $41,789 |
| Profits Per Employee | -$1.87M |
| Employee Count | 57 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 839,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.36 |
| 52-Week Price Change | -63.09% |
| 50-Day Moving Average | 11.40 |
| 200-Day Moving Average | 11.93 |
| Relative Strength Index (RSI) | 72.15 |
| Average Volume (20 Days) | 207,825 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.73M |
| Short Previous Month | 1.68M |
| Short % of Shares Out | 11.77% |
| Short % of Float | 16.39% |
| Short Ratio (days to cover) | 7.94 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 2.38M |
| Gross Profit | -41.02M |
| Operating Income | -76.90M |
| Pretax Income | -105.81M |
| Net Income | -106.64M |
| EBITDA | -74.33M |
| EBIT | -76.90M |
| Loss Per Share | -$8.88 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 115.04M |
| Total Debt | 42.21M |
| Net Cash | 95.71M |
| Net Cash Per Share | $6.50 |
| Equity (Book Value) | 103.23M |
| Book Value Per Share | 7.02 |
| Working Capital | 108.00M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -67.95M |
| Capital Expenditures | -317,000 |
| Depreciation & Amortization | 2.57M |
| Net Borrowing | n/a |
| Free Cash Flow | -68.27M |
| FCF Per Share | -$4.64 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -3,228.34% |
| Pretax Margin | -4,441.86% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -28.33% |
| Shareholder Yield | -28.33% |
| Earnings Yield | -62.01% |
| FCF Yield | -32.38% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $20.20 |
| Price Target Difference | 41.11% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -2.55 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |